Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 272Carcinoma, Non-Small-Cell Lung 195Prostatic Neoplasms 171Stomach Neoplasms 100Lung Neoplasms 93Squamous Cell Carcinoma of Head and Neck 74Head and Neck Neoplasms 69Esophageal Neoplasms 56Neoplasms 47Neoplasm Metastasis 36Pancreatic Neoplasms 31Nasopharyngeal Carcinoma 30Ovarian Neoplasms 27Sarcoma 26Urinary Bladder Neoplasms 25Triple Negative Breast Neoplasms 20Adenocarcinoma 19Carcinoma, Squamous Cell 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Carcinoma, Ovarian Epithelial 15Unspecified Adult Solid Tumor, Protocol Specific 13Carcinoma, Transitional Cell 13Breast Neoplasms, Male 13Adenocarcinoma of Lung 12Salivary Gland Neoplasms 11Laryngeal Neoplasms 11Small Cell Lung Carcinoma 10Inflammatory Breast Neoplasms 10Uterine Cervical Neoplasms 9

Interventions

Androgen Antagonists 2relugolix 1niraparib 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Docetaxel × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡